Radisphere skips RSNA to target hospital executives
Radisphere’s best opportunities, according to Clayton T. Larsen, Radisphere senior vice president of client and network development, are community hospitals with 50 to 400 beds, particularly ones being served by poorly run radiology groups.
Radisphere won’t be at the RSNA meeting this year because its best prospects won’t be there. The RSNA meeting is expected to draw 60,000 attendees, most of whom will be radiologists. None are likely to buy services from the Cleveland, OH-company, which began seven years ago as the teleradiology firm Franklin & Seidelmann, but has since evolved into a national radiology group that competes directly with radiology groups.
Radisphere’s best opportunities, according to Clayton T. Larsen, Radisphere senior vice president of client and network development, are community hospitals with 50 to 400 beds, particularly ones being served by poorly run radiology groups.
Listen now to Larson's comments during an interview with Greg Freiherr, business and technology editor for Diagnostic Imaging.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
